Gyre Therapeutics GC reports stock option holding

Gyre Therapeutics, Inc. executive Joshua Benjamin Bergmann, the company’s GC and Corporate Secretary, reported his initial ownership of a stock option in a Form 3 filing.

Rhea-AI Filing Summary

Gyre Therapeutics, Inc. executive Joshua Benjamin Bergmann, the company’s GC and Corporate Secretary, reported his initial ownership of a stock option in a Form 3 filing. The option gives him the right to buy 47,530 shares of common stock at an exercise price of $8.09 per share.

According to the filing, the option expires on February 27, 2036. One quarter of the option will vest on June 16, 2026, and the remaining three quarters will vest in equal monthly installments over the following three years, as long as he continues serving the company on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bergmann Joshua Benjamin

Role GC and Corporate Secretary

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 47,530 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase 47,530 shares of the Issuer's common stock, one quarter of which will vest on June 16, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Underlying shares: 47,530 shares Exercise price: $8.09 per share Option expiration: February 27, 2036 +2 more

5 metrics

Underlying shares 47,530 shares Common stock underlying reported stock option

Exercise price $8.09 per share Exercise price for stock option right to buy common stock

Option expiration February 27, 2036 Expiration date of reported stock option

Initial vesting date June 16, 2026 One quarter of option vests on this date

Remaining vesting period Three years Remaining three quarters vest monthly over following three years

Key Terms

Stock Option (Right to Buy), vest, exercise price, underlying security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vest financial

"one quarter of which will vest on June 16, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: 8.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: Common Stock"

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GYRE’s GC report in this Form 3 filing?

Joshua Benjamin Bergmann, GC and Corporate Secretary of Gyre Therapeutics (GYRE), reported an initial holding of a stock option. The option covers 47,530 shares of common stock, reflecting his equity-based compensation position with the company.

How many GYRE shares are covered by Bergmann’s stock option?

Bergmann’s stock option covers 47,530 shares of Gyre Therapeutics common stock. This option represents a right to purchase those shares upon vesting and exercise, aligning part of his compensation with the company’s share performance over time.

What is the exercise price of the reported GYRE stock option?

The reported stock option for Gyre Therapeutics (GYRE) has an exercise price of $8.09 per share. This means Bergmann can buy common shares at $8.09 once the option vests, if he chooses to exercise the option before it expires.

When does Bergmann’s GYRE stock option vest?

According to the filing, 25% of the option vests on June 16, 2026. The remaining 75% then vests in equal monthly installments over the next three years, subject to Bergmann’s continued service with Gyre Therapeutics on each vesting date.

When does the reported GYRE stock option expire?

The stock option reported by Gyre Therapeutics (GYRE) executive Joshua Benjamin Bergmann expires on February 27, 2036. He must exercise any vested portion of the option before that expiration date, or the right to purchase those shares will lapse.

Does this GYRE Form 3 show any share purchases or sales?

The Form 3 for Gyre Therapeutics (GYRE) shows an initial holding of a stock option, not open-market trades. It lists Bergmann’s right to buy 47,530 shares via options, with vesting and expiration terms, rather than reporting a purchase or sale transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 09:23 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bergmann Joshua Benjamin

(Last) (First) (Middle)

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/04/2026

3. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GC and Corporate Secretary

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	02/27/2036	Common Stock	47,530	$8.09	D

Explanation of Responses:

1. This option represents a right to purchase 47,530 shares of the Issuer's common stock, one quarter of which will vest on June 16, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Thomas Eastling, as attorney-in-fact for Joshua Bergmann	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)